Background: The aim of this study is to evaluate the clinical outcomes between anti-thymocyte globulin (ATG) and basiliximab induction in deceased donor kidney transplantation (DDKT).
INTRODUCTION
After kidney transplantation, acute rejection is associated with shortened kidney allograft survivals (1) . Therefore, in-duction therapy has been used to prevent acute cellular rejection at the time of transplantation. In the almost center, anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme, Cambridge, MA, USA) and basiliximab (Simulect, Novartis Pharmaceutical Corp., Basel, Switzerland) have been used as an induction therapy for many years. Are there any differences between two agents for induction therapy in terms of safety and efficacy? We did not yet come to the conclusion of this question. Brennan et al. (1) reported that ATG showed superior results in preventing acute cellular rejection in high risk patients. But, Liu et al. (2) concluded that basiliximab may be safer and more preferable option for the induction therapy in kidney transplantation. Neidlinger and Sollinger (3) proposed also that there was insufficient evidence to justify the use of ATG induction in kidney transplantation. So the aim of this study is to evaluate the clinical outcomes between ATG and basiliximab induction in deceased donor kidney transplantation (DDKT). 
MATERIALS AND METHODS

Immunosuppressive therapy
Patients of ATG group received ATG daily for 5 days induction therapy (1.5 mg/kg/day). ATG was diluted in an isotonic solution to make a total volume of 250 mL and then administered by slow, regular intravenous infusion within the 12-hour period prior to revascularization of the graft.
Patients of basiliximab group were given basiliximab, which was administered in two separate 20 mg doses by bolus intravenous injection, the first dose within 2 hours before re-vascularization of the graft and the second dose on day 4 posttransplant.
The maintenance of immunosuppressive regimens was standard triple therapy consisting of tacrolimus, mycophenolate mofetil (MMF) and prednisone throughout the study.
MMF was administered on first postoperative day at a dose of 750 mg twice daily. Tacrolimus was administered on third day posttransplant in the ATG group at a dose of 0.1 mg/kg/day and administrated on first postoperative day in the basiliximab group. The dosage was subsequently adjusted to give a trough concentration of between 8∼10 ng/mL during 3 months, 5∼8 ng/mL during the next 6 months.
All the patients received 500 mg of intravenous methylprednisolone prior to revascularization of the graft during the operation and first day posttransplant. Later, its dose is tapered out. Oral prednisone was subsequently prescribed at a daily dose of 20 mg until 1 month. Then the daily dose was tapered to 5 mg within a year.
Statistical analysis
Statistical analysis was performed using the Student t-test, the Mann-Whitney test, the chi-square test, and the logrank test. The Kaplan-Meier method was used to calculate overall patient and graft survivals. Statistical significance was accepted for P＜0.05, and statistical analysis was carried out using PASW ver. 18.0 (SPSS Inc., Chicago, IL, USA.).
RESULTS
Demographic and clinical data
The demographic and clinical data of the patients that underwent DDKT were shown in Table 1 . No significant differences between two groups were observed in respect to age, sex, and etiology of chronic renal disease in terms of recipient's characteristics. The majority of renal disease in both groups was related to diabetes mellitus nephropathy.
All patients in the both group were first renal transplantation (100%). The mean follow-up period in the ATG and the basiliximab group was 28.7±18.2 months in ATG group and 38.2±24.0 months respectively. All recipients of both group had no donor-specific antibody. Donor age was not significantly different between two groups (P=0.185). 
Postoperative complications
Postoperative complications in the two groups were shown in (Fig. 1 ).
DISCUSSION
Induction therapy is specific therapy given at the time of transplantation to lower the incidence of acute rejection and thus improve allograft survival. Currently, almost 70% of kidney transplantation recipients received induction therapy with either basiliximab or ATG (1) . ATG is a lymphocytedepleting polyclonal antibody that targets multiple immuno-logic epitopes. And basiliximab is a non-lymphocyte-depleting monoclonal antibodies that target the interleukin-2 (IL-2)
receptor (1) .
In this single center study of 37 DDKT performed in adults, we treated the induction therapy for all patients of DDKT with basiliximab or ATG. We applied ATG for relatively poor renal function of donor, which were donor age Various previous studies reported that basiliximab had lower incidence of infection (1, 2, 4, 5) . Similar to those results, our study shows that the infection rate was higher in ATG than basiliximab group, but there was no significant An acute rejection is still the biggest complication to improve the survival of renal transplantation. It increases not only the incidence of early stage kidney non-function and other complications and the treatment cost, but also is an important risk factor leading to late kidney graft loss (6) .
Thus any treatment to prevent and decrease early stage acute rejections would help increase the long-term survival of patients and grafts (7) . An incidence of acute rejection was reported in 20%∼50% (4, 6, (8) (9) (10) . In many studies, there was no significant difference on acute rejection between ATG and basiliximab (2, 3, 5, (10) (11) (12) (13) (14) , whereas some other studies have report that ATG induction group showed lower incidence of acute rejection (1, 15, 16) . In this study, the in-cidence of acute rejection was 15.0% in ATG group and 29.4% in basiliximab group, respectively. Acute rejection was more prevalent in the basiliximab group than ATG group, but there was no statistical significance (P=0.428) which these results were similar to other previous studies.
In this study, despite of small cases of DDKT, DGF, the 1-year patient survival, 1-year graft survival and GFR level by period of recipients were not significantly different in both groups. We found no significant intergroup differences in patient survivals and graft survivals. In many studies, DGF rate was 6%∼40%, 1-year survival rate was about 90% (5, 6, 9, 11, 13, 14, 16) . Our study showed similar results, but we applied ATG criteria to donor of relatively poor renal function. In other words, ATG would be considered as a safe and efficient induction agent even if the donor has a poor renal function.
BK virus associated nephropathy (BKVAN) is major cause
of progressive destruction of allograft in kidney transplantation (17, 18) . An incidence of BKVAN was 1%∼10% of kidney transplant patients and its incidence is increasing recently (19) . BK virus (BKV) is a member of the human polyomavirus family (20) and infection with the virus is common and a majority of adult population is seropositive for the virus (21) . BKV resides dormant in uroepithelial cells and is not known to cause tissue damage in immunocompetent individuals (22) . However, the virus can become reactivated in the setting of immunodeficiency (e.g., secondary to HIV infection or immunosuppressive medications), and result in cellular damage and organ dysfunction(23). 
CONCLUSION
The results showed that patient survival and graft survival after induction of ATG vs. basiliximab of the DDKT were not different. Infection rate was higher in ATG induction group but episodes of acute T-cell mediated rejection were more prevalent in basiliximab induction group. The statistical significance was not found between both groups.
Therefore, both induction agents led to a good patient and graft survival and ATG might be safe and preferable agent for relatively poor renal function of donor in kidney transplantation. Because of the small number of patients in the study and the short-term outcome, these results should be confirmed with larger cohorts to find out the long-term benefits of these two induction therapy.
